Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast
GOTHENBURG, Sweden, February 9, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that on February 17, 2017 the Company will release its financial results for the fourth quarter and year ended December 31, 2016. The topics covered in the year end press release will include a general corporate update and an update on the financial results. In addition, Immunicum is pleased to announce the completion of a corporate website update.
The Company's management team will host a webcast to discuss the Company's financial results and recent corporate developments on Friday, February 17, 2017 at 10:00 a.m. CET / 4:00 a.m EST. The webcast can be accessed at the following link: http://www.redeye.se/liveimmunicum.
At the conclusion of the webcast, individuals with inqueries may call, email or tweet their questions to the following phone number, email address and Twitter handles:
Phone number: +46 (8) 509 316 79
Email address: firstname.lastname@example.org
Twitter Handles: @Immunicum ; @Redeye_
An audio webcast of the conference call can be accessed in the "Events & Presentation" section on the "Investors" page of the Immunicum website at http://immunicum.se/investors/events-presentations/. A replay of the webcast will be available on Immunicum's website shortly after the conclusion of the call and will be archived on the Immunicum website for 30 days following the call.
About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com
For more information, please contact
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
The Company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31